Alzamend Neuro News

Buy Rating Justified by Alzamend Neuro's Promising Alzheimer's Treatments and Attractive Valuation

TipRanksApr 15 05:15 ET

Buy Rating for Alzamend Neuro Amid Promising Alzheimer's Drug Trials and Market Potential

TipRanksDec 19, 2023 05:06 ET

Promising Developments in Alzamend Neuro's Clinical Trials Bolster Buy Rating: A Focused Review on AL001's Potential in Mental Health Treatment

TipRanksOct 24, 2023 13:55 ET

Maxim Group Reaffirms Their Buy Rating on Alzamend Neuro (ALZN)

TipRanksJun 27, 2023 08:15 ET

Maxim Group Initiates Coverage On Alzamend Neuro With Buy Rating, Announces Price Target of $1.5

BenzingaApr 12, 2023 09:31 ET

Ascendiant Sticks to Their Buy Rating for Alzamend Neuro (ALZN)

TipRanksApr 5, 2023 08:41 ET

Alzamend Neuro (ALZN) Gets a Buy From Univest Securities

TipRanksOct 2, 2022 03:35 ET

Univest Securities Sticks to Their Buy Rating for Alzamend Neuro (ALZN)

TipRanksSep 14, 2022 09:00 ET

Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN) and Alzamend Neuro (ALZN)

TipRanksAug 25, 2022 10:45 ET